Pete Bonk
About Pete Bonk
Pete Bonk serves as the Ri Section Councilor and Career Services representative at the American Chemical Society, where he has been a member for 47 years. He has extensive experience in research and development, having held significant roles at various organizations including Purdue Pharma and NuChem Therapeutics.
Work at American Chemical Society
Pete Bonk has been a member of the American Chemical Society (ACS) since 1977, contributing to the organization for 47 years. He currently serves as the Ri Section Councilor and has held the position of Career Services and Former SCHB Officer since 2002. His involvement with ACS spans over two decades, during which he has played a significant role in various initiatives aimed at enhancing career services for members.
Education and Expertise
Pete Bonk holds a Bachelor of Science degree in Chemistry from the University of Michigan, which he earned from 1971 to 1975. He furthered his education at the University of Wisconsin - Madison, where he studied Organic Chemistry and obtained a Doctor of Philosophy degree from 1979 to 1985. His academic background provides a strong foundation for his expertise in medicinal chemistry and business development.
Background in Research and Development
Pete Bonk has extensive experience in research and development across various organizations. He worked at Purdue Pharma L.P. as Principal Scientist and Assistant Director of R&D from 2002 to 2008. Prior to that, he served as Assistant Director of R&D at Rhodes Technologies Inc. from 2006 to 2008. He also held the position of Vice President of R&D at CSCS Corp. from 2009 to 2014, and was a Project Leader at The Dow Chemical Company from 1985 to 1993.
Business Development Experience
Since 2017, Pete Bonk has been involved in business development at NuChem Therapeutics in Montréal, Quebec, Canada. His role focuses on enhancing business development strategies, particularly in medicinal chemistry, through partnerships with organizations such as a Montreal-based Contract Research Organization. He has collaborated with NuChem Therapeutics to strengthen business development activities in the Northeast Corridor.